Sartorius simplifies biologics production with new bioreactor
Company launches BIOSTAT STR Generation 3 bioreactor with BIOBRAIN automation platform.
Engineered to address the rigorous requirements and complexity of biologics manufacture, Sartorius now offers its BIOSTAT STR Generation 3 single-use bioreactor and BIOBRAIN automation platform to change biopharmaceutical process development and manufacturing.
BIOSTAT STR is a robust industrial platform consisting of hardware, software and consumables for single-use process development and commercial biomanufacturing. This generation of bioreactors and Flexsafe STR bags range from 12.5 L to 2000 L in working volume.
The system is powered by BIOBRAIN, a new automation platform that gives biologics manufacturers the flexibility to quickly and easily configure the BIOSTAT STR system to meet their precise needs. Data-driven software, a comprehensive suite of analytical tools and experienced engineering design and support teams enable manufacturers to produce consistent results, even in the setting of changing demands.
Fully integrated and redundant single-use sensors provide real-time data to measure and control key critical process parameters such as pH, DO, viable biomass, glucose, lactate and foam. Non-invasive measurements save set-up time, prevent interface issues and reduce the need for off-line manual sampling. These monitoring and control systems enhance batch-to-batch consistency and operator confidence.
BIOSTAT STR Generation 3 is ready for process intensification and includes functionalities such as feed controls, bleed controls and connectivity to Repligen’s XCell ATF cell retention devices to increase cell density and productivity.
Connection to Umetrics SIMCA enables predictive, multivariate modeling and control, allowing manufacturers to predict yield and optimal harvest time points at the early stages of the perfusion process.
Integration into existing process infrastructure can be achieved in multiple ways: local management via the BIOSTAT STR control tower and BIOBRAIN automation platform with connection to data histories, or full process management via distributed control systems from Emerson, Siemens or Rockwell. An additional feature for BIOSTAT STR Generation 3 is the optional integration of native Emerson DeltaV controls supported by a Sartorius DeltaV library, which affords full access and control from DeltaV systems.
Sartorius engineering and technical field experts help design and implement new facilities and retrofits, address scaling challenges and manage technology transfers. This level of support relieves internal development and manufacturing teams from the burden of developing master status on new technology.
Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance